(Boursier.com) — Adocia a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, today announced positive results in a Phase 2 study, comparing M1Pram to Humalog in people with type 1 diabetes.
The fixed-ratio combination of human insulin analog M1 100 Units/mL and pramlintide 600µg/mL, the only FDA-approved amylin analog (Symlin, AstraZeneca), demonstrated statistically superior weight loss to that of insulin lispro 100 Units/mL. Full results will be communicated at EASD 2022.
©2022 Boursier.com